Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
News|Articles|December 2, 2014
- Pharmaceutical Technology-12-02-2014
- Volume 38
- Issue 12
Sartorius Bioreactor and Microbial Fermenter Increases Efficiency
Sartorius Stedim Biotech’s BIOSTAT A is a compact bioreactor and fermenter with accessible peristaltic pumps, probe ports, and supply connections.
Sartorius Stedim Biotech’s BIOSTAT A is a compact bioreactor and fermenter with accessible peristaltic pumps, probe ports, and supply connections. The ergonomic design features an aeration module that provides automatic flow control, eliminating the need for the manual adjustment of flow meters.
The bioreactor system controls pH and dissolved oxygen (DO) by aeration with four gases: air, Oâ, COâ, and Nâ. The system is equipped with digital pH and DO probes, and the option to monitor and control the system with a tablet or smartphone in any location, inside or outside of the lab. The system is available with single-walled borosilicate glass culture vessels of one-, two-, or five-liter working volumes.
The microbial fermentation system contains two gas lines, air and Oâ, for DO control. The system is equipped with a chiller to remove heat from the device, eliminating the need for a cooling water system.
Sartorius Stedim Biotech
Articles in this issue
almost 12 years ago
VIDEOJET Thermal Ink Printer Offers Increased Resolutionalmost 12 years ago
Ross Planetary Mixers Increase Mixing Optionsalmost 12 years ago
The Bio/Pharma Working Lifealmost 12 years ago
FDA Realigns Drug Inspection and Manufacturing Oversightalmost 12 years ago
Fitzpatrick Roll Compaction Series Improves Accuracyalmost 12 years ago
Drug Scandals Impact Industry in Japanalmost 12 years ago
Securing the Single-Use Supply Chainalmost 12 years ago
Improving Job Market Creates Opportunity for Changealmost 12 years ago
FDA Approves Novel Treatments in 2014almost 12 years ago
Novel Technologies Win CPhI Pharma AwardsRelated to this article
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.